Skip to main content
SpringerLink
Log in

The Neuroprotective and Neuronal Rescue Effect of (-)-Deprenyl

  • Chapter
Apoptosis and Its Modulation by Drugs

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 142))

Summary

(-)-Deprenyl treatment is able to increase the dopaminergic tone in the CNS by several mechanisms. It inhibits the normal metabolic degradation of dopamine and the metabolites formed from the drug reduce the uptake and promote the release of the transmitter. The age-related increase in MAO-B activity can also be blocked by (-)-deprenyl administration, which can decrease the resulting oxidative damage of the CNS. (-)-Deprenyl pretreatment can inhibit the formation of toxins from pre-toxins and their selective uptake into the nerve endings. In small doses (-)-deprenyl is also effective in post-treatment schedules, having a neuronal rescue effect partly due to the inhibition of apoptosis of the neurones by the drug. (-)-Deprenyl is still the most widely used MAO inhibitor in the treatment of Parkinson’s disease (PD). It is administered alone or in combination with levodopa. The treatment can postpone the need for levodopa or potentiate its effect. The usage of (-)-deprenyl treatment in Alzheimer’s disease (AD) is less frequent than in PD, but some results indicate a mild improvement in cognitive functions of the patients with AD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 349.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 449.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anderson AJ, Su JH, Cotman CW (1996) DNA damage and apoptosis in Alzheimer’s disease: colocalization with c-Jun immuno-reactivity, relationship to brain area and the effect of post-mortem delay. J Neurosci 16:1710–1719

    PubMed  CAS  Google Scholar 

  • Anglade P, Michel P, Marquez J, Mouatt-Prient A, Ruberg M, Hirsh EC et al. (1995) Apoptotic degeneration of nigral dopaminergic neurons in Parkinson’s disease. Proc Nat Acad Sci 21:489–493

    Google Scholar 

  • Ansari KS, Yu PH, Kruck TX, Tatton WG (1993a) Rescue of axotomized immature ratfacial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13:4042–4053

    PubMed  CAS  Google Scholar 

  • Ansari KS, Zhang F, Holland DH, Yu PH, Tatton WG (1993b) R(-)-deprenyl, not its major metabolites, rescue axotomized immature facial motoneurons. (Abstract) Soc Neurosci 19:243

    Google Scholar 

  • Baumgarten HG, Zimmermann G (1992) In: Herken H, Hucho F (eds) Selective neurotoxicity (Handbook of Exp Pharm 102). Springer, Berlin Heidelberg New York, pp 225–292

    Google Scholar 

  • Berry M.D, Juorio AV, Paterson IA (1994) Possible mechanism of action of (-)-deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Neurobiology 44:141–161

    CAS  Google Scholar 

  • Birkmayer W, Riederer P, Ambrozi L, Youdim MB (1977) Implications of combined treatment with “Madopar201D; and L-deprenyl in Parkinson’s disease. A long-term study. Lancetl (8009):439–443

    Article  Google Scholar 

  • Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64(2):113–127

    Article  PubMed  CAS  Google Scholar 

  • BuysYM, Trope GE, Tatton WG (1995) (-)-Deprenyl increases the survival of retinal ganglion cells after optic nerve crush. Curr Eye Res 14:119–126

    Article  Google Scholar 

  • Carrillo MC, Kanai S, Nokubo M, Kitani K (1991) (-)-Deprenyl induces activities of both Superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48:517–521

    Article  PubMed  CAS  Google Scholar 

  • Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO (1992) The ability of (-)-deprenyl to increase Superoxide dismutase activities in the rat tissue and brain region selectively. Life Sci 50:1985–1992

    Article  PubMed  CAS  Google Scholar 

  • Carrillo MC, Kanai S, Sato Y, Nokubo M, Ivy GO, Kitani K (1993) The optimal dosage of (-)-deprenyl for increasing Superoxide dismutase activity in several brain regions decreases with age in male Fischer 344 rats. Life Sci 52:1925–1934

    Article  PubMed  CAS  Google Scholar 

  • Chiueh CC, Huang SJ, Murphy DL (1994) Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. J Neural Transm [Suppl] 41:189–196

    CAS  Google Scholar 

  • Clarke PGH (1990) Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol 181:195–213

    Article  PubMed  CAS  Google Scholar 

  • Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turn-over. Ann Neurol 26:689–690

    Article  PubMed  CAS  Google Scholar 

  • Cotman CW Anderson AJ (1995) A potential role for apoptosis in neurodegeneration and Alzheimer’s disease. Mol Neurobiol 10:19–45

    Article  PubMed  CAS  Google Scholar 

  • Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker BB, Mee E (1995) In situ evidence for DNA fragmentation in Huntington’s disease striatum and Alzheimer’s disease temporal lobes. Neuroreport 6:1053–1057

    Article  PubMed  CAS  Google Scholar 

  • Fang J, Zuo DM, Yu PH (1995) Lack of protective effect of R(-)-deprenyl on programmed cell death of mouse thymocytes induced by dexamethasone. Life Sci 57:15–22

    Article  PubMed  CAS  Google Scholar 

  • Finnegan KT, Skratt JS, Irwin I, DeLanney LE, Langston JW (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 184:119–126

    Article  PubMed  CAS  Google Scholar 

  • Freisleben HJ, Lehr F, Fuchs J. (1994) Lifespan of immunosuppressed NMRI-mice is increased by deprenyl. J Neural Transm [Suppl] 41:231–236

    CAS  Google Scholar 

  • Gallagher IM, Clow A, Glover V (1998) Long term administration of (-)-deprenyl increases mortality in male Wistar rats. J Neural Transm [Suppl] 52:315–320

    Article  CAS  Google Scholar 

  • Gerlach M, Riederer P, Vogt H (1996) Effect of adding selegiline to levodopa in early, mild Parkinson’s disease: “on treatment201D; rather than intention to treat analysis should have been used, [letter] BMJ 312:704

    PubMed  CAS  Google Scholar 

  • Gibson CJ (1987) Inhibition of MAO-B, but not MAO-A blocks DSP-4 toxicity on central NE neurones. Eur J Pharmacol 141:135–138

    Article  PubMed  CAS  Google Scholar 

  • Glover V, Gibb C, Sandier M (1986) The role of MAO in MPTP toxicity-A review. J Neural Transm [Suppl] XX 65–76

    Google Scholar 

  • Ham J, Babij C, Whitfield J, Pfarr CM, Lallemand D, Yaniv M, Rubin LL (1995) A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14:927–939

    Article  PubMed  CAS  Google Scholar 

  • Hársing LG, Magyar K, Tekes K, Vizi ES, Knoll J (1979) Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acethylcholine release inhibition. Pol J Pharmacol Pharm 31:297–307

    PubMed  Google Scholar 

  • Hockenbery DM, Oltvai ZN, Xiao-Ming Y, Korsmeyer SJ (1993) Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241–251

    Article  PubMed  CAS  Google Scholar 

  • Jarrott B, Vajda FJE. (1987) The current status of monoamine oxidase and its inhibitors. Med J Aust 146:634–638

    PubMed  CAS  Google Scholar 

  • Javitch JA, d’Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173–2177

    Article  PubMed  CAS  Google Scholar 

  • Jellinger KA (1996) Effect of adding selegiline to levodopa in early, mild Parkinson’s disease: causes of death need confirmation. BMJ [Lett] 312:704–705

    Article  CAS  Google Scholar 

  • Ju WJH, Holland DP, Tatton WG (1994) (-)-Deprenyl alters the time course of death of axotomized facial motoneurons and the hypertrophy of neighboring astrocytes in immature rats. Exp Neurol 126:233–246

    Article  PubMed  CAS  Google Scholar 

  • Kitani K, Kanai S, Sato Y, Ohta M, lvy GO, Carrillo MC (1993) Chronic treatment of (-)-deprenyl prolongs the life span of male Fischer 344 rats: further evidence. Life Sci 52:281–288

    Article  PubMed  CAS  Google Scholar 

  • Knoll J (1987) R-(-)-Deprenyl ((-)-deprenyl, Mogervan) facilitates the activity of the nigro-striatal dopaminergic neuron. J Neural Transm 25:45–66

    CAS  Google Scholar 

  • Knoll J (1988) The striatal dopamine dependence of life span in male rats: longevity study with (-)-deprenyl. Mech Ageing Dev 46:237–262

    Article  PubMed  CAS  Google Scholar 

  • Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandier M (eds) Monoamine oxidases (New Vistas Adv in Biochem Psychopharmacol, vol 5). Raven Press, New York, pp393–408

    Google Scholar 

  • Knoll J, Ecseri Z, Kelemen K, Nivel J, Knoll B (1965) Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155:154–164

    PubMed  CAS  Google Scholar 

  • Knoll J, Yen TT, Kiklya I. (1994) Sexually low performing male rats die earlier than their high performing peers and (-)-deprenyl treatment eliminates this difference. Life Sci 54:1047–1057

    Article  PubMed  CAS  Google Scholar 

  • Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980

    Article  PubMed  CAS  Google Scholar 

  • Langston JW, Langston EB, Irwin I. (1984) MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand 100 [Suppl]:49–54

    CAS  Google Scholar 

  • Lassmann H, Bancher C, Breitschopf H,Wegiel J, Bobinski M, Jeelinger K, Wisniewski HM (1995) Cell death in Alzheimer’s disease evaluated by DNA fragmentation in situ. Acta Neuropathol Ber 89:35–41

    Article  CAS  Google Scholar 

  • Lees AL and the Parkinson’s Disease Research Group of the United Kingdom. (1995) Comparison of therapeutic effects and mortality data of levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 311:1602–1607

    Article  PubMed  CAS  Google Scholar 

  • Lindenboim L, Diamond R, Rothenberg E, Stein R (1995) Apoptosis induced by serum deprivation of PC12 cells is not preceded by growth arrest and can occur at each phase of the cell cycle. Cancer Res 55:1242–1247

    PubMed  CAS  Google Scholar 

  • Magyar K (1991) Neuroprotective effect of deprenyl and p-fluor-deprenyl. Paneuropean Society of Neurology, Second Congress, Vienna, 26

    Google Scholar 

  • Magyar K (1993) Pharmacology of monoamine oxidase type B inhibitors. In: Szelenyi I (ed) Inhibitors of monoamine oxidase B. Birkhauser Verlag, Basel, pp125–143

    Google Scholar 

  • Magyar K (1994) Behaviour of (-)-deprenyl and its analogues. J Neural Transm 41:167–175

    CAS  Google Scholar 

  • Magyar K (1997) The role of the metabolism of (-)-deprenyl in neuroprotection. In: Proceedings of the 11th ESN Meeting. Teelken AW, Korf J (eds) Neurochem 303–308

    Google Scholar 

  • Magyar K, Vizi ES, Ecseri Z, Knoll J (1967) Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol Acad Sci Hung 32(4):377–387

    PubMed  CAS  Google Scholar 

  • Magyar K, Szende B, Lengyel J, Tekes K (1996) The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research. J Neural Transm (Suppl) 48:29–43

    CAS  Google Scholar 

  • Magyar K, Szende B, Haberle D, Gaál J, Tarcali J (1998a) The neuroprotective and neuronal rescue effect of selegiline. 18 th European Winter Conference on Brain Research. Arc 2000 (France). 7-14 March, p42

    Google Scholar 

  • Magyar K, Szende B, Lengyel J, Tarcali J, Szatmári I (1998b) The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm (Suppl) 52:109–123

    Article  CAS  Google Scholar 

  • Maki-Ikola O, Kilkku O, Heinonen E (1996) Effect of adding selegiline to levodopa in early, mild Parkinson’s disease: other studies have not shown increased mortality, [letter] BMJ 312:704–705

    Google Scholar 

  • Milgram NW, Racine RJ. Nellis P. Mendonca A, Ivy GO. (1990) Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci 47:415–420

    Article  PubMed  CAS  Google Scholar 

  • Muller WE, Schroder HC, Ushijima H, Drapper J, Bormann J (1992) gpl20 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantine. Eur J Pharmacol 226:209–214

    Article  PubMed  CAS  Google Scholar 

  • Naoi M, Maruyama W, Yagi K, Youdim M (1998) Anti-apoptotic function of (-)-deprenyl and related compounds. 8th Amine Oxidase Workshop. International Workshop on Monoamine Oxidases, Trace Amines, Neuroprotection and Neuronal Rescue. Balatonöszöd, Lake Balaton, Hungary, 6-10 September pl6

    Google Scholar 

  • Oh C, Murray B, Bhattacharya N, Holland D, Tatton WG (1993) (-)-Deprenyl alters the survival of adult facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in Mnd mutants. J Neurosci Res 38:64–74

    Article  Google Scholar 

  • Olanow CW (1990) Oxidation reactions in Parkinson’s disease. Neurology 40 (10 Suppl 3):32–39

    PubMed  Google Scholar 

  • Olanow CW (1996) Deprenyl in the treatment of Parkinson’s disease: clinical effects and speculations on mechanism of action. J Neural Transm [Suppl] 48:75–84

    CAS  Google Scholar 

  • Olanow CW, Calne D (1991) Does selegiline monotherapy in Parkinson’s disease act by symptomatic or protective mechanisms? Neurology 42:13–26

    Google Scholar 

  • Olanow CW, Godbold JH, Koller W (1996) Effect of adding selegiline to levodopa in early, mild Parkinson’s disease: patients taking selegiline may have received more levodopa than necessary, [letter] BMJ 312:702–703

    PubMed  CAS  Google Scholar 

  • Oltvai ZN, Korsmeyer SJ (1994) Checkpoints of dueling dimers foil death wishes. Cell 79:189–192

    Article  PubMed  CAS  Google Scholar 

  • Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A. (1988) Design and early clinical evaluation of selective inhibitors of monoamine oxidase. Prog Neuropsychopharmacol Biol Psychiatry 12:967–987

    Article  PubMed  CAS  Google Scholar 

  • Parkinson Study Group (1989a) DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 46:1052–1060

    Article  Google Scholar 

  • Parkinson’s Study Group (1989b) Effect of deprenyl on the progression of disability in early Parkinson’s disease. NEJM 321:1364–1371

    Article  Google Scholar 

  • Parkinson’s Study Group (1993) Effects of Tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. NEJN. 328:176–183

    Article  Google Scholar 

  • Parnham MJ (1993) The history of 1-deprenyl. In: Szelenyi I (ed) Inhibitors of monoamine oxidase B. Birkhauser, Basel, pp 237–251

    Google Scholar 

  • Ricci A, Mancini M, Strocchi P, Bongrani, Bronzetti E (1992) Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64 A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor 1-deprenyl. Drugs Exp Clin Res VIII(5):163–171

    Google Scholar 

  • Ross SB, Renyi AL (1976) On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine(DSP-4) on the active uptake of adrenaline. J Pharm Pharmacol 28:458–459

    Article  PubMed  CAS  Google Scholar 

  • Salach JI, Singer TP, Castagnoli N, Trevor A (1984) Oxidation of the neurotoxic amine l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem Biophys Res Comm 125:831–835

    Article  PubMed  CAS  Google Scholar 

  • Salo PT, Tatton WG (1992) Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31:394–400

    Article  PubMed  CAS  Google Scholar 

  • Sandier M (1981) Monoamine oxidase inhibitor efficacy in depression and the “;cheese effect”. Psychol Med 11:455–458

    Article  Google Scholar 

  • SchJingensiepen KH, Wollnik F, Kunst M, Schlingensiepen R, Herdegen T, Brysch W (1994) The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptations in vivo. Cell Mol Neurobiol 14:487–505

    Article  Google Scholar 

  • Simonian NA, Coyle JT (1996) Oxidative stress in neurodegenerative diseases Annu Rev Pharmacol Toxicol 36:83–106

    Article  PubMed  CAS  Google Scholar 

  • Snyder SH, Coyle JT (1969) Regional differences in 3H-norepinephrine and 3H-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther 165:78–86

    PubMed  CAS  Google Scholar 

  • Strolin-Benedetti M, Dostert P. (1989) Monoamine oxidase, brain ageing and degenerative diseases. Biochem Pharmacol 38:561

    Google Scholar 

  • Su JH, Anderson AJ, Cummings BJ, Cotman CW (1994) Immunohistochemical evidence for apoptosis in Alzheimer’s disease. Clin Neurosci Neuropathol 5:2529–2533

    CAS  Google Scholar 

  • Szende B, Magyar K (1998) Apoptotic and anti-apoptotic effect of deprenyl and desmetyl-deprenyl on human cell lines. 8th Amine Oxidase Workshop. International Workshop on Monoamine Oxidases, Trace Amines, Neuroprotection and Neuronal Rescue. Balatonöszöd, Hungary, 6-10 September p 17

    Google Scholar 

  • Takahashi A, Earnshaw WC (1996) ICE-related proteases in apoptosis. Curr Opin Genet Dev 6:50–55

    Article  PubMed  CAS  Google Scholar 

  • Tatton WG (1998) Agents that block mitochondrial initiation of apoptosis: a new opportunity for neuroprotection. Satellite Symposium to the 3rd Congress of the European Federation of Neurological Societies. Selegiline in the Treatment of Neurodegenerative Diseases. Sevilla, Italy, 19 September, p 4

    Google Scholar 

  • Tatton WG, Chalmers-Redman RME (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neuro-degeneration. Neurology 47 (Suppl 3) S171–183

    Article  PubMed  CAS  Google Scholar 

  • Tatton WG, Ju WYL, Holland DP, Tai CE, Kwan MM (1994a) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572–1574

    Article  PubMed  CAS  Google Scholar 

  • Tatton WG, Seniuk NA, Ju WYH, Ansari KS (1994b) Reduction of nerve cell death by deprenyl without monoamine oxidase inhibition. In: Monoamine Oxidase Inhibitors in Neurological Diseases. Lieberman A, Olanow O, Youdim MBH, Tipton K (eds), Raven Press, New York, pp 217–248

    Google Scholar 

  • Tatton WG, Chalmers-Redman RME, Ju WYH, Waida J, Tatton NA (1997) Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J Neural Transm [Suppl] 49:245–268

    CAS  Google Scholar 

  • Tekes K.Tóthfalusi L, Gaál J, Magyar K (1988) Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol J Pharmac Pharm 40:653–658

    CAS  Google Scholar 

  • Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245:519-122

    Google Scholar 

  • Tetrud JW, Langston JW (1992) Protective and preventive therapeutic strategies: monoamine oxidase inhibitors. Neurol-Clin 10(2):541–552

    PubMed  CAS  Google Scholar 

  • Wessel K (1993) MAO-B inhibitors in neurological disorders with special reference to selegiline. In: Szelenyi I (ed) Inhibitors of monoamine oxidase B. Birkhauser Verlag Basel, pp 253–275

    Google Scholar 

  • Wu RM, Chiueh CC, Pert A, Murphy DL (1993) Apparent antioxidant effect of L-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 243:241–248

    Article  PubMed  CAS  Google Scholar 

  • Wu RM, Mohanakumar KP, Murohy DL, Chiueh CC (1994) Antioxidant mechanism and protection of nigral neurones against MPP+ toxicity by deprenyl (selegiline). Ann NY Acad Sci 738:214–221

    Article  PubMed  CAS  Google Scholar 

  • Wyllie AH, Kerr JFR, Currie AR (1986) Cell death: the significance of apoptosis. Int Rev Cytol 68:251–306

    Article  Google Scholar 

  • Yen TT, Knoll J (1992) Extension of lifespan in mice treated with Dinh lang (Policias fruticosum L.) and (-)-deprenyl. Acta Physiol Hung 79:119–124

    PubMed  CAS  Google Scholar 

  • Yoshiyama Y, Yamada T, Asanuma K, Asahi T (1994) Apoptosis related antigen, Le(Y) and nick-end labeling are positive in spinal motor neurons in amyotrophic lateral sclerosis. Acta Neuropathol Berld 88:207–211

    Article  CAS  Google Scholar 

  • Youdim MBH, Finberg JPM (1987) Monoamine oxidase B inhibition and the “cheese effect”. J Neural Transm [Suppl] 25:27–33

    CAS  Google Scholar 

  • Yu PH, Davis BA, Fang J, Boulton AA (1994) Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4 induced noradrenaline depletion in the mouse hippocampus. J Neurochem 63:1820–1828

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. K. Magyar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Szende
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology Toronto Hospital, General Division, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada, M5G 2C4

    Ross G. Cameron M.D., Ph.D.

  2. Banting Institute Department of Clinical Biochemistry, University of Toronto, Toronto, Ontario, Canada, M5G 2C4

    George Feuer Ph.D., C. Med. Sci.

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Magyar, K., Szende, B. (2000). The Neuroprotective and Neuronal Rescue Effect of (-)-Deprenyl. In: Cameron, R.G., Feuer, G. (eds) Apoptosis and Its Modulation by Drugs. Handbook of Experimental Pharmacology, vol 142. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57075-9_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57075-9_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63025-5

  • Online ISBN: 978-3-642-57075-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation